Companies: 10,795·Total market cap: $144.5T
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMRNASDAQHealthcare● Active
$74.39
+$0.26(+0.35%)
Market Cap$6.1B
P/E Ratio
52W High$103
52W Low$36.65

Kymera Therapeutics, Inc. (KYMR) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

kymr · stock forecast · 26 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 26 Wall Street analysts in the past 3 months

SellBuy

Buy

26 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
23
Hold
3
Sell
0
Strong Sell
0
Total: 26 · Buy rate: 88.5%

12-Month Price Target

High

$138

Consensus

$120

+61.9% upside

Low

$106

Median: $119.5 · Last Close: $74.34

The Kymera Therapeutics, Inc. (KYMR) analyst consensus is Buy, based on ratings from 26 Wall Street analysts over the past 3 months. The average 12-month KYMR price target is $120.36, representing +61.9% upside from the current price of $74.34.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $120 (61.9%)

Consensus Target

$120.36

61.9% upside

High Target

$138

85.6%

Low Target

$106

42.6%

Current Price

$74.34

as of today

Based on analyst price targets, the KYMR stock price prediction for the next 12 months ranges from $106 to $138. The consensus KYMR price forecast of $120.36 implies 61.9% upside from the current price of $74.34.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$70.625.00%

1-day model range: $70.27–$70.98. Peak: $70.98 (-5.00%).

Long-Term Stock Price Prediction

⚠️ Long-term projections are hidden until 252 trading days of history (IPO / limited listing). Short-term tab may still show model output.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

7%22%71%
1Buy
3Neutral
10Sell
RSI (14)38.4Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · KYMR · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$73.52BUY
MA 10$77.14SELL
MA 20$79.47SELL
MA 50$82.89SELL
MA 100$81.42SELL
MA 200$0.00NEUTRAL
Current $KYMR · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$74.80SELL
EMA 10$76.35SELL
EMA 20$78.57SELL
EMA 50$81.02SELL
EMA 100$80.93SELL
EMA 200$0.00NEUTRAL
Current $KYMR · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
UBS2026-03-03
Maintains
BuyBuy
Stephens & Co.2026-03-02
Maintains
OverweightOverweight
Citigroup2026-03-02
Maintains
BuyBuy
Piper Sandler2026-02-26
Maintains
OverweightOverweight
BTIG2026-02-26
Maintains
BuyBuy
BTIG2026-02-03
Maintains
BuyBuy
Barclays2026-01-28
Maintains
OverweightOverweight
BTIG2026-01-15
Maintains
BuyBuy
Wolfe Research2026-01-06
Downgrade ↓
OutperformPeer Perform
B. Riley Securities2025-12-22
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Kymera Therapeutics, Inc. (KYMR) stock. Of the recent 117 rating actions, 6 were upgrades and 4 were downgrades. 26 analysts currently cover KYMR.

Analyst Recommendation Trends

Buy ratings33
Hold ratings00
Sell ratings00

KYMR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 3 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$80M

↑ 103.3% YoY

Revenue Next Year

$39M

↓ 50.7% YoY

EPS This Year

$-3.50

EPS Next Year

$-4.30

↑ 22.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast KYMR EPS of $-3.50 for the current fiscal year, based on estimates from 17 analysts. The KYMR revenue forecast is $80M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The KYMR stock forecast is supported by two independent data sources: analyst consensus ratings from 26 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus KYMR price target is $120.36 (+61.9% upside), with an analyst consensus of Buy.

The KYMR short-term stock prediction for tomorrow is $70.62 (-5.00%).

Kymera Therapeutics, Inc. trades on NASDAQ under the ticker KYMR. The KYMR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

KYMR forecast · 8 questions

According to 26 Wall Street analysts, the average 12-month KYMR price target is $120.36, with a high forecast of $138.00 and a low of $106.00. The median price target is shown in the chart above when available. This implies +61.9% potential upside from the current price of $74.34.

KYMR price targetWhat is KYMR price targetKYMR analyst price targetKYMR 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.